Published in Clin Ophthalmol on July 30, 2010
Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clin Ophthalmol (2017) 1.40
Allergic contact dermatitis caused by topical eye drops containing latanoprost. Ann Dermatol (2014) 0.89
Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases. Jpn J Ophthalmol (2012) 0.83
Cross-sectional study of the association between a deepening of the upper eyelid sulcus-like appearance and wide-open eyes. PLoS One (2014) 0.77
Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study. BMC Ophthalmol (2016) 0.76
Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol (2012) 0.76
Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. Eye (Lond) (2016) 0.76
Hirsutism following the use of bimatoprost eyedrops for glaucoma. J Pharmacol Pharmacother (2014) 0.75
Hypertrichosis and Hyperpigmentation in the Periocular Area Associated with Travoprost Treatment. Ann Dermatol (2015) 0.75
A Randomised Open Label Comparative Clinical Trial on the Efficacy of Latanoprost and Timolol in Primary Open Angle Glaucoma. J Clin Diagn Res (2016) 0.75
Critical evaluation of latanoprostene bunod in the treatment of glaucoma. Clin Ophthalmol (2016) 0.75
Prostaglandin-associated periorbitopathy in latanoprost users. Clin Ophthalmol (2014) 0.75
EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol (2015) 0.75
Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications. Clin Ophthalmol (2017) 0.75
The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol (2006) 25.47
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (2002) 14.17
The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol (2000) 12.21
Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol (2003) 8.76
Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol (1998) 7.34
The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol (1998) 6.70
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol (2003) 4.52
A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol (2003) 4.35
Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma (2000) 3.65
Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology (1998) 3.13
Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology (2008) 2.66
Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology (1995) 2.43
Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology (1996) 2.41
Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol (2001) 2.34
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology (2005) 2.30
Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma (2008) 2.28
Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology (1993) 2.10
Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology (2002) 2.02
The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol (2005) 1.97
Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology (2003) 1.96
Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol (2008) 1.94
Treatment for glaucoma: adherence by the elderly. Am J Public Health (1993) 1.90
Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Ophthalmology (2001) 1.90
Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology (2004) 1.89
Prostaglandins and cystoid macular edema. Surv Ophthalmol (2002) 1.88
A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol (2007) 1.86
A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology (1996) 1.84
A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol (1996) 1.80
Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology (1996) 1.76
Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology (2009) 1.75
Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol (1999) 1.74
Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol (2005) 1.72
A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol (1997) 1.70
One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol (2002) 1.70
Side effects associated with prostaglandin analog therapy. Surv Ophthalmol (2008) 1.69
Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma (2001) 1.64
Latanoprost and herpes simplex keratitis. Am J Ophthalmol (1999) 1.63
Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol (2009) 1.59
Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol (2003) 1.59
Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther (2001) 1.59
Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol (2001) 1.56
The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol (2001) 1.54
Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol (2002) 1.54
Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol (1996) 1.52
Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther (2007) 1.52
Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol (2002) 1.52
A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology (2009) 1.49
A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology (2003) 1.48
Target pressure--glaucomatologists' holey grail. Ophthalmology (2000) 1.48
Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma (2007) 1.45
Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf ) (2008) 1.44
A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol (2004) 1.40
Iris cyst secondary to latanoprost mimicking iris melanoma. Am J Ophthalmol (2003) 1.40
Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol (2006) 1.40
Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf ) (2008) 1.39
Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther (2004) 1.38
Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology (1999) 1.36
Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology (1996) 1.36
A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol (2009) 1.34
A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol (2002) 1.32
Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci (2000) 1.32
Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol (2004) 1.31
A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin (2007) 1.30
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther (2003) 1.30
Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol (2005) 1.28
Prostaglandin-induced hair growth. Surv Ophthalmol (2002) 1.28
Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology (2008) 1.27
Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol (2001) 1.26
The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther (2009) 1.26
Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma (2008) 1.26
Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol (2008) 1.24
From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci (2001) 1.24
The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol (2008) 1.24
Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol (2001) 1.24
Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol (2002) 1.24
Anterior uveitis associated with latanoprost. Am J Ophthalmol (1998) 1.23
Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol (2002) 1.22
Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol (1995) 1.22
Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology (1998) 1.21
Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol (2008) 1.20
A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther (2006) 1.19
Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol (2006) 1.18
Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma (2008) 1.17
Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol (2001) 1.17
Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci (2003) 1.17
Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol (1997) 1.15
Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol (2001) 1.15
Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol (2007) 1.15
Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol (2008) 1.14
The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol (1997) 1.13
Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology (2006) 1.13
Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol (2008) 1.13
Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci (1984) 1.12
Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci (2006) 1.12
Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol (2004) 1.11
Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma (2001) 1.11
Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol (2005) 1.11
Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther (2003) 1.09
Scleritis. Surv Ophthalmol (2005) 3.12
Factors determining visual outcome in endogenous Candida endophthalmitis. Retina (2012) 2.67
Syphilitic retinitis and uveitis in HIV-positive adults. Clin Experiment Ophthalmol (2010) 2.26
Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol (2011) 1.85
Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand (2006) 1.66
Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmology (2011) 1.60
Assisted local anaesthesia for endoscopic dacryocystorhinostomy. Clin Experiment Ophthalmol (2007) 1.47
Parasites and the eye. Hosp Med (2003) 1.36
Outcome of intravitreal triamcinolone in uveitis. Ophthalmology (2005) 1.23
The ocular manifestations of inflammatory bowel disease. Curr Opin Ophthalmol (2006) 1.18
Expression of toll-like receptor 4 and its associated lipopolysaccharide receptor complex by resident antigen-presenting cells in the human uvea. Invest Ophthalmol Vis Sci (2004) 1.14
External dacryocystorhinostomy: assessing factors that influence outcome. Orbit (2010) 1.07
Ocular myositis. Curr Allergy Asthma Rep (2013) 1.06
Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol (2015) 1.02
Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocul Pharmacol Ther (2007) 1.00
Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ther (2006) 0.97
Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina (2013) 0.93
Behçet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol (2011) 0.92
Scedosporium prolificans sclerokeratitis 10 years after pterygium excision with adjunctive mitomycin C. Clin Experiment Ophthalmol (2005) 0.92
Scleritis: Immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res (2013) 0.91
What is new HLA-B27 acute anterior uveitis? Ocul Immunol Inflamm (2011) 0.91
Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol (2011) 0.90
Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clin Ophthalmol (2008) 0.87
Visual outcomes for optic nerve sheath fenestration in pseudotumour cerebri and related conditions. Clin Experiment Ophthalmol (2006) 0.87
Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features. J Glaucoma (2008) 0.86
The role of mucosal flaps in external dacryocystorhinostomy. Orbit (2010) 0.83
Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol (2011) 0.83
Diagnostic vitreous biopsy in patients with uveitis: a useful investigation? Clin Experiment Ophthalmol (2005) 0.81
The role of PAMPs and DAMPs in the pathogenesis of acute and recurrent anterior uveitis. Br J Ophthalmol (2009) 0.80
Pharmacotherapeutic efficacy of preservative-free intravitreal triamcinolone acetonide. Expert Opin Pharmacother (2010) 0.79
Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol (2010) 0.79
Acute anterior uveitis in Sydney. Ocul Immunol Inflamm (2012) 0.78
Ocular manifestations of seronegative spondyloarthropathies. Curr Opin Ophthalmol (2014) 0.77
Scleritis: challenges in immunopathogenesis and treatment. Discov Med (2013) 0.77
Intraocular inflammation: its causes and investigations. Curr Allergy Asthma Rep (2008) 0.77
Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy. Ocul Immunol Inflamm (2012) 0.77
Multiresistant Pseudomonas keratitis. Clin Experiment Ophthalmol (2010) 0.76
Limbal dermoid epithelium shares phenotypic characteristics common to both hair epidermal and limbal epithelial stem cells. Curr Eye Res (2013) 0.76
Ockham's razor revisited: decreased visual acuity secondary to keratoconus in a patient with intracranial hypertension. BMJ Case Rep (2011) 0.75
Treatment of chronic uveitic cystoid macular oedema. Clin Experiment Ophthalmol (2009) 0.75
New agents for treating dry eye syndrome. Curr Allergy Asthma Rep (2013) 0.75
Reply: To PMID 22298012. Retina (2013) 0.75
Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications? Med J Aust (2008) 0.75
Retinal detachment in cytomegalovirus retinitis: intravenous versus intravitreal therapy. Clin Experiment Ophthalmol (2003) 0.75
Devastating bilateral optic nerve leukaemic infiltration. Clin Experiment Ophthalmol (2011) 0.75
The length of superficial temporal artery biopsies. ANZ J Surg (2007) 0.75
TATTOO-ASSOCIATED UVEITIS WITH CHOROIDAL GRANULOMA: A RARE PRESENTATION OF SYSTEMIC SARCOIDOSIS. Retin Cases Brief Rep (2016) 0.75
Graft-free Molteno tube insertion: 10-year outcomes. Br J Ophthalmol (2010) 0.75
Choroidal Thickness and Microperimetry Sensitivity in Age-Related Macular Degeneration. Ophthalmic Res (2017) 0.75
Investigating cataract referral practices used by Australian optometrists. Clin Exp Optom (2014) 0.75
Genetics in Age-Related Macular Degeneration: Current Research and Implications for Future Treatment. Asia Pac J Ophthalmol (Phila) (2015) 0.75
Intraocular triamcinolone for giant cell arteritis? Arch Ophthalmol (2010) 0.75
Publication output of senior academic ophthalmologists in Australia and New Zealand. Clin Experiment Ophthalmol (2014) 0.75
Otago Glaucoma Surgery Outcome Study: cytology and immunohistochemistry of trabeculectomy blebs. Invest Ophthalmol Vis Sci (2013) 0.75
Ocular complications associated with systemic medications used in allergy/immunology practice. Curr Allergy Asthma Rep (2013) 0.75